Pulmonary Pressure Level Compound The Treatment Of Hypoxic Pulmonary Hypertension

Purpose: After thorough discussion on the formation of Hypoxic Pulmonary Hypertension (HPH) and review of prevention and treatment to HPH according to both Chinese and western medicine, the author holds the view that HPH, one of serious complications of the Chronic Obstructive Pulmonary Disease (COPD), is the key factor of aggravated pulmonary heart disease in western medicine while lung deficiency, phlegm retention and blood stasis contribute to the pathology of secondary HPH in Traditional Chinese Medicine (TCM). Therefore, the author carried out the research through clinical observations to further explore the effective mechanism of Feiyanping, a compound prescribed by Prof. Jin Miaowen from her clinical experience for many years in combined Chinese and western medicine for above pathological changes.Methods: Divide all HPH cases into two groups at random, 28 cases in Feiyanping group and 19 cases inNifedipine group as contrast. Results: MPAP, blood viscosity, plasma viscosity, fibrinogen, HCT and PaCO2 decrease obviously after treatment (P＜0.05). while PaO2 increases at the same time(P＜0.05),which are similar to that in Nifedipine group(P＞0.05). However, compared by the Nifedipine group, the clinical symptoms and physical signs receive better improvements in Feiyanping group.Conclusion: The results show that Feiyaping, a compound of Chinese Material Medica (CMM) with promising prospect through further research and exploration, can relieve HPH and improve hypoxia as well as hemorheological situation.